ESTRO 2024 - Abstract Book

S2209

Clinical - Upper GI

ESTRO 2024

chosen for dCRT due to location of tumor. 12 patients (40%) received SIB dose. 22 of 30 (73%) received at least five cycles of chemotherapy. Seven grade III acute (six hematological, one dysphagia) and no grade III chronic toxicities were observed. At last follow-up, 67% of the patients had complete response. Median follow-up time was nine months (range: 3-14 months). Median disease-free survival (DFS) is 14 months and median overall survival (OS) was not reached. Those who received less than five cycles of chemotherapy had higher numbers of acute myelosuppression (p=0.019) and deranged RFTs (p=0.003). Acute grade I dysphagia was seen more commonly in SIB arm (7 vs. 4, p=0.026). However, chronic grade I odynophagia was more frequent in non-SIB patients (3 vs. 0, p<0.001). Number of chemotherapy cycles and radiation dose did not affect response, DFS or OS.

Disease status at last follow-up

Number (N=30)

Percentage (%)

Complete response

20

67

Residual

lesion/locoregional

8

26

recurrence

Distant metastasis/new primary

1

3

Residual disease + distant metastasis 1

3